Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001

Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001

Sarepta Therapeutics, today provided the following update on the Biologics License Application (BLA) for SRP-9001 (delandistrogene moxeparvovec), which is currently under review for the treatment of ambulant individuals with Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the DMD gene.

• Following discussions with FDA, the Agency has indicated that, subject to the completion of the BLA review, it is working toward potentially granting an accelerated approval for SRP-9001, initially for use in Duchenne patients ages 4-5 years old.
• EMBARK, the global, randomized, double-blind, placebo-controlled Phase 3 trial of SRP-9001, is the proposed confirmatory study. The Agency has informed Sarepta that, in addition to confirming the results of the initial BLA approval, if the trial meets its objectives the Agency intends to entertain a non-age-restricted expansion of the SRP-9001 label based upon the review of the EMBARK data. EMBARK is fully enrolled, with top-line results expected in the fourth quarter of 2023.
• The FDA has also informed Sarepta that it requires modest additional time to complete the review, including final label negotiations and postmarketing commitment discussions, and that it anticipates that the review will be complete by June 22, 2023.

Sarepta will remain in a quiet period for the duration of the BLA review. Please read the full press release here.

Do you want to know more?

• To find out more about Duchenne science, gain crucial knowledge and support, please join us on our Science on Tour workshops. We are coming to 30 locations across the UK in 2023 – book your FREE place here now. 
• SAVE THE DATE: Action Duchenne’s International Conference 2023 will be held on the 10th and 11th November and is an amazing opportunity to meet with those involved in every aspect of Duchenne, from families, clinicians, researchers and pharmaceutical companies.